Condition
Inflammatory
Total Trials
4
Recruiting
1
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 1 (1)
Trial Status
Completed2
Terminated1
Recruiting1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07271381Not ApplicableRecruiting
THREAT: Testing Harms Related to Exposure to Allergenic and Epithelial Toxins
NCT03912428Phase 1Terminated
Novel PET Radioligand as an Inflammatory Biomarker in Musculoskeletal Conditions
NCT05598086Not ApplicableCompleted
Anti-fibrinolytic and Anti-inflammatory Effects of Local Infiltration of Tranexamic Acid in Patients With Calcaneal Fractures
NCT01231477Completed
Cytokines and Sevoflurane During Surgery
Showing all 4 trials